Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

ACADIA H Form 4 June 10, 20									PPROVA	AL
	UNITED	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							3235	-0287
if no lo subject Sectior Form 4 Form 5 obligat	to 16. or Filed put ions Section 17(STATEMENT OF CHANGES IN BE SECURIT Filed pursuant to Section 16(a) of the Section 17(a) of the Public Utility Holding					inge Act of 1934,	Estimated burden hou response	ed average hours per	
may co <i>See</i> Ins 1(b).	truction			-	-	ny Act of 1				
(Print or Type	e Responses)									
1. Name and Address of Reporting Person <u>*</u> Brege Laura			2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ACAD]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/06/2014			Director 10% Owner Officer (give title below) Other (specify below)				
			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
SAN DIE	GO, CA 92121						Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivativo	e Securities A	Acquired, Disposed	of, or Beneficia	lly Owne	d
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		ate, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3,	(A) or d of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature Indirect Beneficia Ownersh (Instr. 4)	al 1ip
Reminder: R	eport on a separate line	e for each clas	s of secu	urities bene	Perse infor requi	ons who re mation con red to resp ays a curre	or indirectly. spond to the colle tained in this forn ond unless the fo ontly valid OMB co	n are not orm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	D
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year	(Instr. 8)	Acquired (A or Disposed (D) (Instr. 3, 4, and 5)		(
			Code V	(A) (D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock option (right to buy)	\$ 21.99	06/06/2014	А	12,500	<u>(1)</u>	06/05/2024	Common Stock	12,500	

Reporting Owners

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) 25% of the shares subject to the stock option vest and become exercisable at the end of each 3-month period following the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(